Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-04457845 in Osteoarthritis of the Knee
NCT00981357Phase 2Completed
- Sponsor
- Pfizer
- Start
- Nov 2009
- Primary completion
- May 2010
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of JZP-150 in knee osteoarthritis (OA) (4 arms), sponsored by Pfizer. Primary endpoints: WOMAC Pain sub-score at 8 weeks and Safety and tolerability of PF-04457845 at 10 weeks. Started Nov 2009; status: completed.
02
Drugs
JZP-150
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT00981357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00981357.